Centre de Lutte contre le Cancer Francois Baclesse

Caen 14076

0 studies enrolling now · 4 studies all time

What they study most

Acute Kidney Injury (AKI), Endometrial Neoplasms, HNSCC for Phase 2 Dose Expansion, Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, NSCLC for Phase 2 Dose Expansion, UC (Urothelial Cancer)

Studies at this site

• Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors — Completed
• Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) — Completed
• Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma — Completed
• Observational Study to Evaluate the Epidemiology of Surgical-induced Acute Kidney Injury — Completed